Probabilities of treatment effects in complete or culprit-only revascularization for NSTEMI a Bayesian re-analysis of the SLIM trial /
The completeness of revascularization in patients presenting with non-ST-elevation myocardial infarction (NSTEMI) and multivessel disease (MVD) remains understudied. The SLIM trial previously demonstrated a significant reduction in a composite endpoint of all-cause death, non-fatal myocardial infarc...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2026
|
| Sorozat: | AMERICAN HEART JOURNAL
296 |
| Tárgyszavak: | |
| doi: | 10.1016/j.ahj.2026.107369 |
| mtmt: | 36945589 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/39847 |
| LEADER | 03152nab a2200421 i 4500 | ||
|---|---|---|---|
| 001 | publ39847 | ||
| 005 | 20260410154428.0 | ||
| 008 | 260410s2026 hu o 000 eng d | ||
| 022 | |a 0002-8703 | ||
| 024 | 7 | |a 10.1016/j.ahj.2026.107369 |2 doi | |
| 024 | 7 | |a 36945589 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a eng | ||
| 100 | 1 | |a Heuts Samuel | |
| 245 | 1 | 0 | |a Probabilities of treatment effects in complete or culprit-only revascularization for NSTEMI |h [elektronikus dokumentum] : |b a Bayesian re-analysis of the SLIM trial / |c Heuts Samuel |
| 260 | |c 2026 | ||
| 300 | |a 10 | ||
| 490 | 0 | |a AMERICAN HEART JOURNAL |v 296 | |
| 520 | 3 | |a The completeness of revascularization in patients presenting with non-ST-elevation myocardial infarction (NSTEMI) and multivessel disease (MVD) remains understudied. The SLIM trial previously demonstrated a significant reduction in a composite endpoint of all-cause death, non-fatal myocardial infarction (MI), repeat revascularization, and stroke with complete revascularization under a frequentist framework. This post-hoc Bayesian re-analysis offers a probabilistic interpretation beyond conventional significance testing.The primary composite endpoint was analyzed as in the original trial, while secondary endpoints of the composite were evaluated individually. Analyses under multiple priors assessed robustness. The minimal clinically important difference (MCID) was defined as 5% absolute risk difference (ARD) for the composite endpoint and 1% for individual endpoints. The primary model used a weakly informative prior on the log relative risk (RR) scale within a normal-normal Bayesian framework.478 patients were randomized (complete: n=240; culprit-only: n=238). The posterior median RR for the composite endpoint was 0.41 (95% credible interval [CrI] 0.22-0.76), corresponding to an ARD of -7.9% (95%CrI -10.4% to -3.2%). The probability of any benefit was 99.8%, and the probability of meeting the MCID was 91.2%. For repeat revascularization, the ARD was -8.3% (95%CrI -10.0% to -4.5%), with a >99.9% probability of clinically relevant benefit. For non-fatal MI, the ARD was -2.8% (95%CrI -4.2% to 0.9%), with a 94.8% probability of benefit. Results were consistent across all priors.Complete revascularization provides a high probability of clinically meaningful benefit in NSTEMI patients with MVD, primarily through reductions in non-fatal MI and repeat revascularization. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 1 | |a Pustjens Tobias F S |e aut |
| 700 | 0 | 1 | |a Lux Árpad |e aut |
| 700 | 0 | 1 | |a Gabrio Andrea |e aut |
| 700 | 0 | 2 | |a van 't Hof Arnoud W J |e aut |
| 700 | 0 | 2 | |a Rasoul Saman |e aut |
| 700 | 0 | 2 | |a SLIM trial investigators |e aut |
| 700 | 0 | 2 | |a Veenstra Leo |e aut |
| 700 | 0 | 2 | |a Camaro Cyril |e aut |
| 700 | 0 | 2 | |a Ruiters Lex |e aut |
| 700 | 0 | 2 | |a Ruzsa Zoltán |e aut |
| 700 | 0 | 2 | |a Piroth Zsolt |e aut |
| 700 | 0 | 2 | |a Ilhan Mustafa |e aut |
| 700 | 0 | 2 | |a Vainer Jindrich |e aut |
| 700 | 0 | 2 | |a Gho Ben |e aut |
| 700 | 0 | 2 | |a Berta Balazs |e aut |
| 700 | 0 | 2 | |a Jambri Zoltan |e aut |
| 700 | 0 | 2 | |a et. al. |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/39847/1/Heuts2026.pdf |z Dokumentum-elérés |